

unexecuted

PATENT

Attorney's Docket No. 1887-111 MIS:jb

Applicant or Patentee: KENNETH NICHOLAS DOLYNCHUK, et al.

Serial or Patent No.: 0 / _____

Filed or Issued: _____

For: USE OF TRANSGLUTAMINASE INHIBITOR FOR THE TREATMENT OF SCAR TISSUE

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37 CFR 1.9 (f) and 1.27(d))—NONPROFIT ORGANIZATION**

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION UNIVERSITY OF MANITOBA

ADDRESS OF ORGANIZATION 105 Administration Building, Winnipeg,
Manitoba, Canada, R3T 2N2.

TYPE OF ORGANIZATION

- ☒ UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION
- ☐ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501 (a) and 501 (c)(3))
- ☐ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA
(NAME OF STATE _____)
(CITATION OF STATUTE _____)
- ☐ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501 (a) and 501 (c)(3)) IF LOCATED IN THE UNITED STATES OF AMERICA
- ☐ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA
(NAME OF STATE _____)
(CITATION OF STATUTE _____)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code with regard to the invention entitled

USE OF TRANSGLUTAMINASE INHIBITOR FOR THE TREATMENT OF SCAR TISSUE

by inventor(s) KENNETH NICHOLAS DOLYNCHUK; and JOHN MICHAEL BOWNESS

described in

- ☐ the specification filed herewith.
- ☐ application serial no. 0 / _____, filed _____.
- ☐ patent no. _____, issued _____.

15250780

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

**NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27).*

NAME _____

ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

NAME _____

ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any charge in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING _____

TITLE IN ORGANIZATION _____

ADDRESS OF PERSON SIGNING _____

SIGNATURE _____ Date _____

PATENT

Attorney's Docket No. 1887-111 MIS:jb

Applicant or Patentee: KENNETH NICHOLAS DOLYNCHUK, et al.

Serial or Patent No.: 08 / 307,621

Filed or Issued: March 23, 1992 (International)

For: USE OF TRANSGLUTAMINASE INHIBITOR FOR THE TREATMENT OF SCAR TISSUE

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37 CFR 1.9 (f) and 1.27(d))—NONPROFIT ORGANIZATION**

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION UNIVERSITY OF MANITOBA

ADDRESS OF ORGANIZATION 105 Administration Building, Winnipeg,
Manitoba, Canada, R3T 2N2.

TYPE OF ORGANIZATION

- ☒ UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION
- ☐ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501 (a) and 501 (c)(3))
- ☐ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA
(NAME OF STATE _____)
(CITATION OF STATUTE _____)
- ☐ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501 (a) and 501 (c)(3)) IF LOCATED IN THE UNITED STATES OF AMERICA
- ☐ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA
(NAME OF STATE _____)
(CITATION OF STATUTE _____)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code with regard to the invention entitled

USE OF TRANSGLUTAMINASE INHIBITOR FOR THE TREATMENT OF SCAR TISSUE
by inventor(s) KENNETH NICHOLAS DOLYNCHUK; and JOHN MICHAEL BOWNESS

described in

- ☐ the specification filed herewith.
- ☒ application serial no. 08 / 307,621, filed _____.
- ☐ patent no. _____, issued _____.

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27).

NAME _____

ADDRESS _____

☐ INDIVIDUAL

☐ SMALL BUSINESS CONCERN

☐ NONPROFIT ORGANIZATION

NAME _____

ADDRESS _____

☐ INDIVIDUAL

☐ SMALL BUSINESS CONCERN

☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Mr. T. G. Falconer

TITLE IN ORGANIZATION Vice-President (Administration)

ADDRESS OF PERSON SIGNING Room 202 Administration Bldg.

SIGNATURE _____

Date Sept. 28, 1994

unexecuted

Combined Declaration and Power of Attorney for United States Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled: **USE OF TRANSGLUTAMINASE INHIBITOR FOR THE TREATMENT OF SCAR TISSUE**, the specification of which was filed as PCT International Application No. PCT/CA92/00123 on 23 March 1992.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, S.1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, S.119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)	Priority Claimed	
	Yes	No

(Number)	(Country)	(Day/Month/Year Filed)
----------	-----------	------------------------

I hereby claim the benefit under Title 35, United States Code, S.120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, S.112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, S.1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

U.S. Application(s):

(Appln. Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)

PCT Application designating the U.S.:

(Appln. Serial No.)	(Filing Date)	(U.S. Serial Nos Assigned [if any])
---------------------	---------------	-------------------------------------

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

Peter W. McBurney, Reg. No. 19,352; Michael I. Stewart, Reg. No. 24,973; Thomas T. Rieder, Reg. No. 22,862; Roger T. Hughes, Reg. No. 25,265; John H. Woodley, Reg.

No. 27,093; Stephen J. Perry, Reg. No. 32,107; Patricia A. Rae, Reg. No. 33,570 and John R. Orange, Reg. No. 29,725.

Send correspondence to:

SIM & McBURNEY
Suite 701
330 University Avenue
Toronto, Ontario, M5G 1R7, Canada

Direct telephone calls to:

Name: M.I. Stewart

at

SIM & McBURNEY
(416) 595-1155

Full name of sole or first inventor: Kenneth Nicholas Dolynchuk

Inventor's signature _____

Date

Residence: Winnipeg, Manitoba, Canada

Citizenship: Canadian

Post Office Address: University of Manitoba
770 Bannatyne Avenue
Winnipeg, Manitoba
Canada, R3E 0W3

Full name of second inventor: John Michael Bowness

Inventor's signature _____

Date

Residence: Winnipeg, Manitoba, Canada

Citizenship: Canadian

Post Office Address: University of Manitoba
770 Bannatyne Avenue
Winnipeg, Manitoba
Canada, R3E 0W3

Combined Declaration and Power of Attorney for United States Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled: **USE OF TRANSGLUTAMINASE INHIBITOR FOR THE TREATMENT OF SCAR TISSUE**, the specification of which was filed as PCT International Application No. PCT/CA92/00123 on 23 March 1992.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, S.1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, S.119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority Claimed
Yes No

(Number)

(Country)

(Day/Month/Year Filed)

I hereby claim the benefit under Title 35, United States Code, S.120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, S.112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, S.1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

U.S. Application(s):

(Appln. Serial No.)

(Filing Date)

(Status)

(patented, pending, abandoned)

PCT Application designating the U.S.:

(Appln. Serial No.)

(Filing Date)

(U.S. Serial Nos Assigned [if any])

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

Peter W. McBurney, Reg. No. 19,352; Michael I. Stewart, Reg. No. 24,973; Thomas T. Rieder, Reg. No. 22,862; Roger T. Hughes, Reg. No. 25,265; John H. Woodley, Reg.

No. 27,093; Stephen J. Perry, Reg. No. 32,107; Patricia A. Rae, Reg. No. 33,570 and John R. Orange, Reg. No. 29,725.

Send correspondence to:

SIM & MCBURNEY
Suite 701
330 University Avenue
Toronto, Ontario, M5G 1R7, Canada

Direct telephone calls to:

Name: M.I. Stewart

at
SIM & MCBURNEY
(416) 595-1155

Full name of sole or first inventor: Kenneth Nicholas Dolynchuk

Inventor's signature

K. Dolynchuk

3/10/94.

Date

Residence: Winnipeg, Manitoba, Canada

Citizenship: Canadian

Post Office Address: University of Manitoba
770 Bannatyne Avenue
Winnipeg, Manitoba
Canada, R3E 0W3

Full name of second inventor: John Michael Bowness

Inventor's signature

J. Bowness

3/10/94

Date

Residence: Winnipeg, Manitoba, Canada

Citizenship: Canadian

Post Office Address: University of Manitoba
770 Bannatyne Avenue
Winnipeg, Manitoba
Canada, R3E 0W3

Declared before me on October 3, 1994

Charles K. Parag

*A Commissioner of Oaths for Manitoba

My Commission expires 12.01.95.